AbstractIntroduction. The use of testosterone replacement therapy (TRT) in hypogonadal men with prostate cancer (PC) on active surveillance (AS) has been c
...Talzenna and Akegga? 2:18 How effective has PSMA been at helping patients delay chemotherapy? 5:08 What was the state of activesurveillance in 2023? 5:56 What is Prostox and can it apply to spot radiation? 7:49 What was the state of Pluvicto as a treatment in 2023? 10:02 How have...
...of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional activesurveillance prostate cancer database. Exogenous testosterone has long been attributed to the development and progression of prostate cancer. In fact...
In this video, Dr. Aday discusses the latest advancements in activesurveillance for prostate cancer. He explains the history of prostate cancer diagnosis and the limitations of the PSA test. He outlines the criteria for eligibility for activesurveillanceand the protocol for monitoring...
...the US and internationally. Renowned physicians from different specialties will be covering topics including advanced cancer, activesurveillance, radiation treatment, imaging, erectile dysfunction, and incontinence. The conference is led by Mark Moyad, MD, who moderates the Q+A sessions...
Testosterone Therapy in Men on ActiveSurveillance(2022) Tristan Chun, Jacob Tannenbaum, Haley Watts, Igor Voznesensky, Wael Almajed, and Wayne J.G. Hellstrom* Abstract In recent decades, although prostate cancer (PCa) mortality has dramatically decreased, addressing the quality of life for...
...on the use of testosterone replacement therapy among patients with prostate cancer, including in the setting of screening, activesurveillance, and after treatment for localized prostate cancer. Beginning, Dr. Khera noted that there has been a paradigm shift with respect to the association...
...the US and internationally. Renowned physicians from different specialties will be covering topics including advanced cancer, activesurveillance, radiation treatment, imaging, erectile dysfunction, and incontinence. The conference is led by Mark Moyad, MD, who moderates the Q+A sessions...
...Mark Moyad, MD, MPH asks Matthew Cooperberg, MD, MPH, about the use of Avodart (dutasteride) and Proscar (finasteride) in men on activesurveillance. Dr. Cooperberg explains that the early belief that these medications increased the incidence of more aggressive prostate cancers was mistaken...
"I'll never forget that phone call in December 2010. The doctor's name flashed on caller ID. I knew the verdict was in on my prostate biopsy. I held my breath as the urologist told me I had cancer. I had done some homework but nothing prepared me for that call on a Friday evening. There's no way...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.